Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF)

Condition: Prostate CancerIntervention: Device: AR-v7 assaysSponsors: Duke University; Weill Medical College of Cornell University; Johns Hopkins University; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Epic Sciences; Prostate Cancer FoundationNot yet recruiting - verified October 2014

http://clinicaltrials.gov/ct2/show/NCT02269982?lup_s=10%2F01%2F2014&lup_d=30

Source: ClinicalTrials.gov - October 20, 2014 Category: Research Source Type: clinical trials